Invenomic Capital Management LP bought a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 53,149 shares of the medical research company's stock, valued at approximately $10,444,000.
Several other institutional investors have also modified their holdings of IQV. Synergy Asset Management LLC acquired a new stake in IQVIA during the fourth quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter worth approximately $60,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Stock Performance
NYSE IQV opened at $148.90 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The business's 50 day moving average is $163.91 and its two-hundred day moving average is $188.25. The stock has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the company earned $2.54 earnings per share. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have commented on IQV shares. Mizuho dropped their price objective on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Finally, StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $231.71.
Check Out Our Latest Report on IQVIA
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
